Hantz Financial Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.81M Sell
7,345
-8,538
-54% -$2.17M 0.02% 364
2026
Q2
$4.78M Sell
15,883
-1,790
-10% -$540K 0.06% 197
2026
Q1
$5.85M Buy
17,673
+6,350
+56% +$2.16M 0.09% 157
2025
Q4
$4.5M Sell
11,323
-1,823
-14% -$807K 0.07% 208
2025
Q3
$6M Buy
13,146
+12,767
+3,369% +$5.2M 0.09% 188
2025
Q2
$124K Buy
+379
New +$105K ﹤0.01% 712

Other funds holding ALNY

Hantz Financial Services's ALNY Position: Q3 2026 in Review

Hantz Financial Services reduced its Alnylam Pharmaceuticals (ALNY) stake by 54% in Q3 2026, selling an estimated $2.17M and leaving 7,345 shares worth $1.81M. The position accounts for 0.02% of the portfolio, ranked #364.

Hantz Financial Services first reported a position in ALNY in Q2 2025 and has held it in 6 quarters since. The position peaked at $6M in Q3 2025. 633 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Hantz Financial Services held 7,345 shares of Alnylam Pharmaceuticals worth $1.81M as of Q3 2026.
  • Hantz Financial Services sold 8,538 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $2.17M.
  • Alnylam Pharmaceuticals made up 0.02% of Hantz Financial Services's portfolio in Q3 2026, its #364 holding.
  • Hantz Financial Services first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Hantz Financial Services's Alnylam Pharmaceuticals position peaked at $6M in Q3 2025.
  • 633 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Hantz Financial Services's 13F filing for Q3 2026, filed 9 Nov 2026.